BMG889121031 - Common Stock
EV stocks have broadly underperformed the market in 2024, which has, in turn, created a number of opportunities to buy at a bargain.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal...
It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 ...
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist...
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing...
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!
Pre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning!
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive multiple sclerosis (MS) with intranasal foralumab.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced an update on the company's progress in treating non-active secondary progressive multiple sclerosis (MS).
shapecharge Biotech Tiziana Life Sciences (NASDAQ:TLSA) Friday announced that five out of six patients in the FDA-authorized Expanded Access Program showed...
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being...
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes...
Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday.